JBC Anatrace, Inc.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M303150200 on May 1, 2003

J. Biol. Chem., Vol. 278, Issue 33, 30441-30449, August 15, 2003
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/33/30441    most recent
M303150200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Janssen, E.
Right arrow Articles by Dzeja, P. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Janssen, E.
Right arrow Articles by Dzeja, P. P.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Impaired Intracellular Energetic Communication in Muscles from Creatine Kinase and Adenylate Kinase (M-CK/AK1) Double Knock-out Mice*

Edwin Janssen {ddagger}, Andre Terzic §, Bé Wieringa {ddagger}  and Petras P. Dzeja §

From the {ddagger}Department of Cell Biology, University Medical Center, University of Nijmegen, The Netherlands and §Division of Cardiovascular Diseases, Departments of Medicine, Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905

Received for publication, March 27, 2003


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Previously we demonstrated that efficient coupling between cellular sites of ATP production and ATP utilization, required for optimal muscle performance, is mainly mediated by the combined activities of creatine kinase (CK)- and adenylate kinase (AK)-catalyzed phosphotransfer reactions. Herein, we show that simultaneous disruption of the genes for the cytosolic M-CK- and AK1 isoenzymes compromises intracellular energetic communication and severely reduces the cellular capability to maintain total ATP turnover under muscle functional load. M-CK/AK1 (MAK=/=) mutant skeletal muscle displayed aberrant ATP/ADP, ADP/AMP and ATP/GTP ratios, reduced intracellular phosphotransfer communication, and increased ATP supply capacity as assessed by 18O labeling of [Pi] and [ATP]. An analysis of actomyosin complexes in vitro demonstrated that one of the consequences of M-CK and AK1 deficiency is hampered phosphoryl delivery to the actomyosin ATPase, resulting in a loss of contractile performance. These results suggest that MAK=/= muscles are energetically less efficient than wild-type muscles, but an apparent compensatory redistribution of high-energy phosphoryl flux through glycolytic and guanylate phosphotransfer pathways limited the overall energetic deficit. Thus, this study suggests a coordinated network of complementary enzymatic pathways that serve in the maintenance of energetic homeostasis and physiological efficiency.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
In tissues with high and sudden energy demand, creatine kinase (CK)1- and adenylate kinase (AK)-catalyzed reactions form the principal pathways securing efficient communication between the subcellular compartments responsible for production and utilization of metabolic energy (16).

Adenylate kinases (AK, EC 2.7.4.3 [EC] ), an evolutionary conserved family of enzymes that catalyzes the reaction ATP + AMP {leftrightarrow} 2 ADP (7), have been implicated in cellular adenine nucleotide homeostasis (8). cDNAs for five isoforms of AK (AK1–AK5) along with the variant of AK1 (AK1{beta}, a membrane-bound form with a presumed role in cell cycle regulation) have been cloned from metabolically active tissues (912). Mammalian skeletal muscle is particularly rich in AK1, the major isoform of the family (9), present in the sarcoplasm, and clustered along the myofibrillar I-band or bound as AK1{beta} to membranes (1315). By donating the energy of the {beta}-phosphoryl group of ATP/ADP to the cellular energetic pool, AK isoenzymes protect cells against energy deprivation in periods of high metabolic demand (6, 1620). The different intracellular localizations and distinct kinetic properties of AK isoforms permit the formation of a coordinated enzymatic network for nucleotide-mediated metabolic signaling, coupling myofibrillar, nuclear, or sarcolemmal energy-dependent processes with mitochondrial energetics (2123).

Creatine kinases (CK, EC 2.7.3.2 [EC] ) catalyzing the reaction MgADP + CrP2 + H+ {leftrightarrow} Cr + MgATP2 belong to a smaller and evolutionary younger family of enzymes with a role in high energy phosphoryl transfer and cellular energy buffering (1, 5, 24). Creatine kinases are foremost found in cells with high peak demands in metabolic energy such as the brain, heart, or skeletal muscle (1, 5). In skeletal muscle, the principal CK isoform is the cytosolic isoform, MM-CK, a homodimer mainly present as a soluble protein in the cytosol and bound to the myofibrillar M- and I-bands (13) as well as to the sarcoplasmic reticulum membranes (25). Skeletal muscle also contains an additional mitochondrial CK isoform (ScCKmit), which amounts to 1–10% of the total CK activity depending on the type of muscle fiber (26, 27). This CK member associates and functionally interacts with the adenine nucleotide translocator and voltage-dependent anion channel in the mitochondrial inner and outer membrane (2830), providing an efficient ATP export and metabolic signal reception pathway (31).

AK and CK in concert with nucleoside diphosphokinase (NDPK) and the enzymes that function in the glycolytic phosphotransfer pathway form the cellular energetic infrastructure responsible for effective handling and distribution of high energy phosphoryl (~P) groups throughout the structured muscle environment (5, 6, 24, 3234). In this network, AK- and CK-mediated reactions play a complementary and functionally alternate role (18, 27, 35, 36). By pharmacological inhibition of the CK circuit, it has been demonstrated that an increase in AK-mediated phosphotransfer may compensate for the loss of CK-activity (17). Likewise, in skeletal muscles carrying a null mutation in either the M-CK or AK1 gene, leading to complete lack of corresponding protein expression and activity, an adaptive rewiring of flux through the remaining intact phosphotransfer circuit occurs (6, 18, 19). In addition, M-CK and AK1 mutant muscles respond with similar but not identical ultrastructural and molecular adaptations, suggesting an inherent plasticity of the bioenergetic network (6, 24, 3739).

Although progress has been made in our understanding of individual phosphotransfer reactions, the consequences of combined deletion of major AK and CK isoforms remain unknown. Here, we report on the effects deleting both the AK1 and M-CK proteins in a single cell-type skeletal muscle fiber of a double knock-out mouse. Use of this model provides us with a unique opportunity to assess the significance of the activities of mitochondrial CK, glycolytic enzymes, and NDPK-mediated phosphotransfer reactions in muscle physiology and metabolism. Monitoring intracellular phosphotransfer kinetics by [18O]phosphoryl labeling revealed that lack of AK1 and M-CK resulted in a serious impairment of communication between ATP-generating and ATP-consuming cellular sites. As a consequence, AK1/M-CK-deficient muscles had a reduced ability to sustain the dynamic fluctuations in ATP/ADP/AMP nucleotide metabolism and overall cellular ATP turnover during functional load despite increased high energy phosphoryl flux through alternative glycolytic and guanylate phosphotransfer pathways. These data provide further evidence for the existence of a fully integrated high energy phosphoryl transfer system with a high degree of functional plasticity required for optimal muscle energetics.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Generation of M-CK/AK1-deficient Mice—Gene-targeted AK1-deficient mice were derived from mouse embryonic stem cells carrying a replacement mutation in the AK1 gene. Creatine kinase knock-out mice were derived from embryonic stem cells carrying a replacement mutation in the M-CK gene. Cohorts of AK1/ and M-CK/ animals were generated and maintained as previously described (24, 39). AK1 and M-CK knock-out mice were cross-bred to obtain animals that were heterozygous for both AK1 and M-CK alleles, and these animals were subsequently mated to obtain homozygous double mutants. Genotyping for wild-type and mutant AK1 and M-CK alleles was performed using a PCR assay as described previously (6, 40). Lack of AK1 and M-CK protein activity was confirmed by Western blot and zymogram analysis. Gastrocnemius and soleus muscles from age matched homozygous M-CK/AK1-deficient (MAK=/=) and wild-type control animals also having a 50–50% C57BL/6 x 129/Ola-mixed inbred background were used for all of the studies. The investigation conformed to the Guidelines for the Care and Use of Laboratory Animals of the Dutch Council and the National Institutes of Health and were approved by the Institutional Animal Care and Use Committee at the University of Nijmegen and the Mayo Clinic.

High energy Phosphoryl Transfer—ATP turnover and phosphoryl flux through AK, CK, and glycolytic systems were measured in intact gastrocnemius-plantaris-soleus (GPS) muscle complex using the [18O]phosphoryl labeling technique (16, 17, 21, 41). Mice were anesthetized with pentobarbital (Beuthanasia D) (100 mg/kg intraperitoneal) and injected with heparin (50 units of intraperitoneal) prior to muscle dissection. Isolated mouse GPS muscle was preincubated for 12 min at room temperature in a medium containing (in mM) 137 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 1 NaH2PO4, 20 HEPES, 0.05 EDTA, 5 glucose, and 24 NaHCO3 (pH 7.4). The muscle complex was then rapidly transferred into a medium enriched with 30% 18O-water (Isotec Inc.) and paced at 2 Hz exactly as described previously (6). After 3 min of 18O labeling, muscles were freeze-clamped using liquid N2 and extracted in a solution containing 0.6 M HClO4 and 1 mM EDTA. Protein content was determined using a protein assay kit (Bio-Rad). Cellular ATP, ADP, GTP, GDP, inorganic phosphate, creatine phosphate (CrP), and glucose 6-phosphate (Glc-6-P) were purified and quantified using high performance liquid chromatography (17, 41). To obtain information on basal levels and turnover rates of phosphoryl-containing metabolites, isolated mouse GPS muscle was treated identically but without pacing. Samples containing phosphoryls of {gamma}-ATP, {beta}-ATP, {beta}-ADP, {gamma}-GTP, {beta}-GTP, {beta}-GDP, inorganic phosphate, and CrP as glycerol 3-phosphate were converted to trimethylsilyl derivatives. 18O enrichment of phosphoryls in glycerol 3-phosphates was determined with a Hewlett-Packard 5980B gas chromatograph mass spectrometer (6).

High Energy Phosphoryl Transfer Rates—Total cellular ATP turnover was estimated from the total number of 18O atoms that appeared in phosphoryls of Pi, CrP, {gamma}-ATP, {beta}-ATP, {beta}-ADP, {gamma}-GTP, {beta}-GTP/GDP, and Glc-6-P. Net AK-, CK-, and hexokinase-catalyzed phosphotransfers were determined from the rate of appearance of 18O-containing phosphoryls in {beta}-ATP and ADP and CrP and Glc-6-P, respectively (6, 17, 41, 42).

Metabolite Levels—ATP, ADP, GTP, and GDP levels were quantified in muscle perchloric extracts by use of high pressure liquid chromatography (21, 41). AMP, ADP, CrP, muscle lactate, and glucose 6-phosphate levels were determined using coupled enzyme assays (21, 24). Muscle inorganic phosphate level was determined using the EnzChek phosphate assay kit (Molecular Probes).

Zymogram Analysis and Enzyme Activity—Homogenates from freshly excised GPS muscles (10% w/v) were prepared in SETH buffer (in mM: 250 sucrose, 2 EDTA, 10 Tris-HCl (pH 7.4)) at 4 °C. GPS extracts were diluted 1:1 in 30 mM Na3PO4 buffer (pH 7.4) containing 0.05% v/v Triton X-100, 0.3 mM dithiothreitol, and a complete protease inhibitor mixture (Roche Applied Science). Muscle extracts were incubated for 30 min at room temperature and centrifuged for 20 min at 11,000 x g, and an aliquot (1–5 µl) was applied to agarose gels (Alameda, CA). AK1 and creatine kinase isoenzymes were separated electrophoretically and stained for enzyme activity (6, 43). CK and AK activities were measured from whole hind limb muscle extracts (6) using a CK NAC (N-acetyl-L-cysteine)-activated kit (Roche Applied Science) and a coupled enzyme system, respectively (21).

Western Blot Analysis—Skeletal muscles were excised, pulverized with a mortar and pestle using liquid N2, and extracted in a buffer containing 50 mM NaCl, 60 mM Tris-HCl (pH 7.5), 5 mM EDTA, and 0.2% Triton X-100 to which a complete protease inhibitor mixture was added. Extracts were centrifuged (10 min, 8000 x g, 4 °C), and proteins were separated on 10% SDS-polyacrylamide gels before being electrophoretically transferred onto nitrocellulose membranes. M-CK and AK1 proteins were detected using antibodies raised against chicken M-CK (44) and mouse AK1-glutathione S-transferase fusion proteins (15). Aldolase antibody (Rockland, Gilbertsville, PA) was used as a control. Immunocomplexes were visualized by chemiluminescence using a secondary antibody coupled to horseradish peroxidase and exposure to Kodak X-Omat AR films.

Actomyosin Contraction—Actomyosin contraction was measured using an established superprecipitation method (45, 46). Excised femoral quadriceps muscles (muscles from two mice combined) were pulverized with mortar and pestle using liquid N2 and extracted in a buffer containing 0.6 M KCl, 0.04 M NaHCO3, 0.01 M Na2CO3, 4 mM dithiothreitol, and a complete protease inhibitor mixture. Extracts were homogenized (3 x 5 s) with a blender (Polytron), maintained at 4 °C for 10–15 min, and centrifuged (30 min, 9500 x g, 4 °C). The supernatant was gently diluted with 10 volumes of ice-cold water containing 0.5 mM dithiothreitol and maintained at 4 °C for 30 min. The solution was centrifuged (15 min, 7000 x g,4 °C), and the precipitate dissolved in a buffer containing 0.6 M KCl, 20 mM Tris-HCl (pH 7.4), and the complete protease inhibitor mixture. Skeletal muscle actomyosin was stored at –20 °C after mixing with an equal volume of glycerol. Superprecipitation was measured in a buffer containing 0.8 mg/ml skeletal muscle actomyosin, 0.8 mM CaCl2, 2 mM MgCl2, 50 mM KCl, 1 mM EGTA, and 20 mM Tris-HCl (pH 6.8) at 25 °C. The change in absorbance at 660 nm was followed after the addition of ADP (0.2 or 2 mM), phosphoenolpyruvate (PEP; 2 mM), CrP (2.0 mM), or ATP (2 mM). Three measurements for each genotype (muscles from 2 mice/sample combined) were performed and statistically compared.

Statistics—Data are presented as mean ± S.E. Student's t test for unpaired samples was used for statistical analysis, and p < 0.05 was considered significant.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Generation of M-CK/AK1 Double Gene Knock-out Mice—To generate a mouse model lacking cytosolic AK1 and M-CK isoforms, single mutant animals carrying a homozygous null mutation in the AK1 gene (6) or the M-CK gene (24) were mated. Subsequent cross-breeding of the F1 males and females with the heterozygous M-CK+//AK1+/ genotype gave litter with normal size. Among an offspring of 175 pups analyzed, 9 animals were M-CK/ and AK1/ (hereon referred to as MAK=/=), indicating normal Mendelian segregation (1 in 16 expected). Zymogram and Western blot analysis confirmed complete absence of M-CK and AK1 protein and enzymatic activity in these animals (Fig. 1). MAK=/= mice showed no overt abnormalities, bred normally when maintained as a separate lineage over multiple (now >6) generations, and had normal life expectancy.



View larger version (32K):
[in this window]
[in a new window]
 
FIG. 1.
Lack of AK1 and M-CK in skeletal muscle of double mutant M-CK/AK1 mice. A, zymogram analysis of homogenates from the GPS muscle complex from wild-type and MAK=/= mice. Native proteins were electrophoretically separated on agarose gels and stained for AK and CK activity. Note absence of AK1 and M-CK activities but preserved ScCKmit activity in MAK=/= muscles. B, Western blot using anti-M-CK and AK antibodies demonstrating absence of M-CK and AK1 proteins in gastrocnemius homogenates from MAK=/= mice. A (weak) band migrating at slightly higher molecular weight than MM-CK represents the cross-reactive mitochondrial ScCKmit isoform. Aldolase signals are shown as controls. C, mutations in the AK1 and M-CK genes revealed by PCR genotype analysis. PCR analysis was designed to specifically distinguish between wild-type and mutant alleles. Genomic DNA from tail biopsies was used as template.

 

Cellular Energetics in Resting and Contracting MAK=/= Muscle—Genetic deletion of M-CK and AK1 produced a dramatic reduction in the amount of 18O labeling of the pools of CrP, {beta}-ATP, and {beta}-ADP in skeletal muscle. Compared with wild type, 18O-metabolic labeling of CrP was decreased from 8.8 ± 0.4 to 5.4 ± 0.2% in MAK=/= resting non-contracting muscle, a reduction of 39% (p < 0.05, n = 6) (Fig. 2A). Stimulation of contractile activity further aggravated the difference in metabolic labeling of CrP between wild-type and mutant muscles, changing from 17.2 ± 1.2% in wild-type to 8.0 ± 0.5% in knock-out muscle (p < 0.05, n = 6), a reduction of 54% (Fig. 2A). On average, muscle stimulation at 2 Hz increased 18O labeling of CrP by 95% in wild type but gave only a 49% elevation in MAK=/= mutant muscle. This increase in [18O]CrP labeling despite the absence of M-CK could be attributed to metabolic flux through the mitochondrial ScCKmit reaction, which is still functionally active in MAK=/= mutant muscles. Indeed, MAK=/= muscles had a residual CK activity of 1.5 ± 0.1 µmol CrP·min1·mg protein1 (n = 3) due to the presence of ScCKmit, which is at 8% of total CK activity in wild-type controls. AK-catalyzed phosphotransfer activity assessed by 18O incorporation in the {beta}-phosphoryl group of ATP was 1.8 ± 0.2% in non-contracting wild-type muscle and increased to 6.3 ± 0.5% in contracting muscle (Fig. 2B). However, AK-catalyzed {beta}-phosphoryl labeling was dramatically reduced in MAK=/= muscles when compared with wild type (by 68 and 85% in resting and contractile state, respectively) with values of 0.6 ± 0.06% in non-contracting muscle and 0.9 ± 0.1% in 2-Hz paced muscle (p < 0.05, n = 6) (Fig. 2B). These results indicate that both CK- and AK-mediated phosphoryl exchange rates increase with metabolic demand, but absolute and relative capacities for up-regulation are severely impaired when M-CK and AK1 are both lacking.



View larger version (20K):
[in this window]
[in a new window]
 
FIG. 2.
Compromised cellular energetics in MAK=/= skeletal muscle. A, reduced CK phosphotransfer in MAK=/= skeletal muscle. Percentage of CrP-phosphoryl oxygens replaced with 18O reflecting CK-catalyzed phosphotransfer in wild-type (n = 6) and MAK=/= (n = 6) GPS muscle is shown. B, dramatically reduced AK phosphotransfer in MAK=/= skeletal muscle. Percentage of {beta}-ATP-phosphoryl oxygens replaced with 18O as an indicator of AK-catalyzed phosphotransfer in wild-type (n = 6) and MAK=/= (n = 6) GPS muscles. C, CrP levels in resting and contracting wild-type and MAK=/= skeletal muscles. CrP levels were measured in wild-type (n = 6) and MAK=/= (n = 6) GPS muscles, incubated for 3 min in 18O-water at rest or paced at 2 Hz. D, reduced capacity to maintain Pi levels in contracting MAK=/= skeletal muscle. Pi was measured in wild-type (n = 6) and MAK=/= (n = 6) GPS muscle incubated for 3 min in 18O-water at rest or paced at 2 Hz. Star indicates significant difference between the groups. WT, wild type.

 

Moreover, a prominent difference in total ATP levels was seen in non-contracting muscles with 27.5 ± 0.9 nmol ATP·mg protein1 in wild type and only 21.9 ± 1.2 nmol ATP·mg protein1 in MAK=/= muscle (p < 0.05, n = 6 each). Conspicuously, in contracting double knock-out MAK=/= muscles, total ATP levels were well maintained compared with wild type (26.8 ± 0.3 nmol ATP·mg protein1 versus 25.2 ± 1.6 nmol ATP·mg protein1, respectively; p > 0.05, n = 6 each). These results suggest that coupling between metabolic energy salvage systems in MAK=/= muscles may be less tight under resting conditions but becomes partly restored under conditions of increased energy demand. It is conceivable that different thresholds in ATP/ADP/AMP ratios are necessary to switch-on alternative pathways for energy homeostasis. Indeed, the ATP/ADP ratio, a kinetic index of ~P utilization and replenishment, was decreased from 8.4 ± 0.2 to 5.9 ± 0.1 in non-contracting muscles and from 6.5 ± 0.2 to 5.6 ± 0.1 in contracting MAK=/= muscles when compared with wild-type controls, respectively (p < 0.05, n = 6). Moreover, the ADP/AMP ratio was significantly higher in non-contracting MAK=/= muscle and MAK=/= muscle under workload when compared with wild type: 9.4 ± 0.4 versus 8.0 ± 0.3 (p < 0.05, n = 6) and 8.3 ± 0.3 (n = 6) versus 6.7 ± 0.4 (n = 5, p < 0.05), respectively. The ATP/AMP ratio in resting muscle was lower in MAK=/= muscle than in wild type (54 ± 3 versus 63 ± 5, respectively; n = 6, p < 0.02), whereas in the contracting wild-type (n = 5) and mutant muscle (n = 6), the ATP/AMP ratio was equally maintained (42 ± 4 versus 42 ± 2). These results indicate that in the absence of AK1 and M-CK, the dynamics of adenine nucleotide metabolism is affected with an apparently less efficient ~P trafficking among separate adenine nucleotide pools.

Upon initiation of contraction, CrP levels in wild-type muscles decreased from 62.2 ± 2.6 nmol CrP·mg protein1 in the resting state to 31.5 ± 3.0 nmol CrP·mg protein1 in the active state, a reduction of 49%. In double mutants, a reduction only by 21% was observed (from 57.4 ± 1.4 nmol CrP·mg protein1 in muscle at rest to 45.5 ± 3.4 nmol CrP·mg protein1 in active muscle; p < 0.05, n = 6) (Fig. 2C). This indicates that the total CrP level does not correlate with muscle genotype when measured at rest but is differentially affected by the absence of M-CK/AK1 under conditions of higher metabolic demand.

Intracellular levels of Pi resulting from hydrolytic cleavage of ATP were similar in wild-type and MAK=/= muscles at rest (39.0 ± 1.8 versus 39.5 ± 0.6 nmol Pi·mg protein1). Upon functional load, however, the level of Pi increased by 20% in MAK=/= but was still significantly lower compared with the 44% increase of Pi in wild-type muscle (46.8 ± 2.2 versus 56.7 ± 2.7 nmol Pi·mg protein1 in MAK=/= versus wild type; p < 0.05, n = 6) (Fig. 2D). Accordingly, the CrP/Pi ratio, an index of the cellular energetic status, was significantly higher in the contracting MAK=/= muscle (1.0 ± 0.1 versus 0.6 ± 0.1; p < 0.05, n = 6) compared with wild-type controls (n = 6). In non-contracting muscle, this ratio was maintained at similar levels of 1.6 ± 0.1 versus 1.5 ± 0.1 in wild type and MAK=/=, respectively (p > 0.05, n = 6). These results indicate that, in the absence of M-CK and AK1, the dynamics of CK (i.e. mitochondrial CK-driven) catalysis and Pi utilizing and/or producing reactions are sufficient to maintain cellular metabolite levels at rest but become inadequate with increased metabolic demand.

Loss of AK- and CK-supported Contraction in MAK=/= Actomyosin—In skeletal muscle, M-CK is clustered at the M-line and I-band of myofibers where it regenerates ATP to sustain myosin ATPase activity (13, 24). AK1 also localizes on the myofibrillar I-band where it may work as an ATP regenerator to support muscle contraction (13, 21, 47). To determine whether this cellular AK1 and M-CK partitioning has functional significance, we compared the contractile properties of actomyosin complexes isolated from wild-type and MAK=/= muscles. Using wild-type actomyosin complexes, in the presence of 0.2 mM ADP, AK1-supported induction of contraction was observed (Fig. 3A). Similar contractile characteristics were seen in the presence of 2 mM CrP based on the M-CK activity that remained in the actomyosin complex after isolation. However, the AK1- and M-CK-supported contractions were abolished in actomyosin complexes isolated from MAK=/= muscles (Fig. 3A). Lack of contraction in wild-type actomyosin complexes in the presence of ADP was also observed with pharmacological inhibition of the AK circuit by diadenosine pentaphosphate, Ap5A (data not shown). The addition of 0.2 mM exogenous ATP as a "direct" substrate caused wild-type actomyosin complex to contract with a maximum amplitude of 0.51 ± 0.02 absorbance units·min1·mg protein1 (n = 3) (Fig. 3B). The onset of contraction was, however, delayed in comparison when ATP was delivered via AK1 and M-CK enzymes that co-purified with the actomyosin complex (Fig. 3, A and B). On average, in wild type, the times to onset of contraction after addition of 0.2 mM ADP and 2.0 mM CrP (plus 0.2 mM ADP) were tcontr, ADP = 28 ± 14s(n = 3) and tcontr, CrP = 15 ± 4s(n = 3), respectively, whereas after direct addition of 0.2 mM ATP, a significantly longer tcontr, ATP = 334 ± 13s(n = 3; p < 0.01) was required to initiate contraction. These results suggest that the actomyosin-associated M-CK and AK1 enzymes serve to channel ATP molecules and thereby provide the myosin ATPase microenvironment with preferential access to metabolic energy.



View larger version (16K):
[in this window]
[in a new window]
 
FIG. 3.
Impaired contractile properties in MAK=/= skeletal muscle actomyosin rescued by pyruvate kinase activity. A, loss of AK- and CK-mediated contraction in MAK=/= actomyosin. Contractile recordings (n = 3; preparation from 2 animals/sample) in the presence of 0.2 mM ADP and 2.0 mM CrP of wild-type (open circles) and MAK=/= (closed circles) skeletal muscle actomyosin are shown. B, effects of ATP from different sources on initiation of wild-type actomyosin contraction. Time to onset of contraction measured (n = 3) in the presence of exogenous ATP (closed squares) and ATP generated by AK/CK-mediated catalysis (open squares). C, pyruvate kinase-mediated contraction in wild-type and MAK=/= actomyosin. Contractile recordings (n = 3) in the presence of 2 mM ADP and 2 mM PEP of wild-type (open squares) and MAK=/= (closed squares) skeletal muscle actomyosin. Representative recordings are shown in A and B. WT, wild type.

 

Although lack of cytosolic M-CK and AK1 phosphotransfer blunted CrP- and ADP-supported actomyosin contraction, activation of pyruvate kinase-catalyzed ATP production by the glycolytic substrate phosphoenolpyruvate (PEP) secured contraction in both wild-type and MAK=/= actomyosin complexes (Fig. 3C). PEP at 2.0 mM produced contraction in MAK=/= actomyosin at approximately similar rates as in wild type, i.e. 0.064 ± 0.008 (n = 3) in wild-type and 0.05 ± 0.01 (n = 2) absorbance units·min1·mg protein1 in mutant actomyosin (Fig. 3C). Thus, the ability of actomyosin to contract using ATP delivered through the glycolytic pathway was not affected in the MAK=/= muscle, suggesting that alternative safeguarding routes for high energy phosphoryl transfer are operational in the absence of M-CK and AK1.

Glycolytic and Guanylate Metabolism in MAK=/= Muscle— Studies in AK1 or M-CK single mutant mice and cell model systems suggest a compensatory interchange between the AK/CK circuits and the glycolytic machinery for energy production (4, 6, 16, 33, 39, 48). We determined here that 18O-metabolic labeling of Glc-6-P by hexokinase, the initial step in the glycolytic cascade, was significantly increased from 8.1 ± 0.9% (n = 6) in the wild-type to 18.9 ± 0.9% (n = 6) in MAK=/= muscle (p < 0.05) at a labeling rate of 1.0 ± 0.1 and 3.6 ± 0.5 nmol·min1·mg protein1 (p < 0.05, n = 6) (Fig. 4A), respectively. In line with this finding, the total Glc-6-P content in MAK=/= muscle contracting at 2 Hz was higher than in wild type (12.9 ± 1.3 versus 5.9 ± 0.3 nmol Glc-6-P·mg protein1, respectively, p < 0.05, n = 6). These results implicate elevated glycolytic phosphotransfer activity that could compensate for lack of metabolic flux through the AK1- and M-CK-mediated reactions. However, lactate levels remained unchanged in the contracting MAK=/= muscle (50 ± 2 versus 47 ± 2 nmol lactate·mg protein1 in mutant versus wild-type muscles; n = 6), suggesting a coordinated elevation of pyruvate oxidation, i.e. mitochondrial Krebs cycle activity in conjunction with accelerated aerobic glycolysis.



View larger version (13K):
[in this window]
[in a new window]
 
FIG. 4.
Increased hexokinase-catalyzed Glc-6-P turnover and guanine nucleotide metabolism in MAK=/= skeletal muscle. A, percentage of Glc-6-P phosphoryl oxygens replaced with 18O as an indicator of glycolytic flux rate measured in wild-type (n = 6) and MAK=/= (n = 6) GPS muscles paced for 3 min at 2 Hz. B, increased {gamma}-GTP phosphate turnover in MAK=/= skeletal muscle. Percentage of {gamma}-GTP phosphoryl oxygens replaced with 18O as an indicator of enzyme activity catalyzing GTP production measured in wild-type (n = 6) and MAK=/= (n = 6) GPS muscles paced for 3 min at 2 Hz. C, increased {beta}-GTP/GDP phosphate turnover in MAK=/= skeletal muscle. Percentage of {beta}-GTP/GDP phosphoryl oxygens replaced with 18O as an indicator of guanylate kinase-catalyzed phosphotransfer measured in wild-type (n = 6) and MAK=/= (n = 6) GPS muscles paced for 3 min at 2 Hz. WT, wild type.

 

Remodeling of intracellular high energy phosphoryl fluxes through guanylate phosphotransfer circuits may provide additional compensation for deficits in the cellular phosphotransfer network (6, 18). Guanine and adenine nucleotide metabolism is intertwined through NDPK, guanylate kinase, and succinate thiokinase-catalyzed reactions (42, 4951). Notably, the percentage of {gamma}-GTP 18O labeling was significantly higher in MAK=/= muscle (22 ± 2% in MAK=/= versus 13 ± 1% in wild-type, respectively; p < 0.05, n = 6) (Fig. 4B), indicating an increased flux through GTP-metabolizing enzymes such as succinyl-CoA synthase in the Krebs cycle and/or NDPK. Moreover, in support of enhanced guanylate phosphotransfer, an increased turnover of {beta}-phosphoryls in GTP and GDP was observed in MAK=/= muscle. The percentage of combined {beta}-GTP/GDP 18O labeling was 2.8 ± 0.1 (n = 3) and 4.5 ± 0.3 (n = 3) in wild-type and MAK=/= skeletal muscles, respectively (p < 0.05; Fig. 4C), indicating increased guanylate kinase-catalyzed phosphotransfer in the MAK=/= muscle. Consequently, the increased guanine nucleotide contribution to cellular energetics resulted in a 2-fold reduction in the ATP/GTP ratio in mutant muscle (41 ± 3 versus 78 ± 3 in MAK=/= and wild-type muscle, respectively; p < 0.05, n = 6). Thus, in response to combined AK1/M-CK deficiency, mutant muscles demonstrate elevated glycolytic and guanine nucleotide phosphotransfer metabolism.

Disrupted Intracellular Energetic Communication in MAK=/= Muscles—Efficient removal of ADP and Pi released in the hydrolysis of ATP is a prerequisite for optimal muscle function (52, 53). Pi produced by cellular ATPase activity in one compartment must be captured by ATP-supplying pathways to regenerate ATP in another compartment. The [18O]phosphoryl labeling technique permits assessment of metabolite exchange among different cellular sites (54). The [18O]Pi/[18O]{gamma}-ATP ratio, an index for intracellular phosphotransfer communication, was significantly reduced in MAK=/= muscles (0.45 ± 0.03 versus 0.66 ± 0.03; p < 0.05, n = 6), i.e. by 32% compared with the wild type (Fig. 5A). Although other factors could contribute to the observed changes, reduction of the [18O]Pi/[18O]{gamma}-ATP ratio is in line with the compromised ability of mutant muscle to maintain metabolite levels and ratios. In this regard, the lower [18O]Pi/[18O]{gamma}-ATP ratio in contracting MAK=/= muscle was accompanied by increased 18O labeling of {gamma}-ATP (22.2 ± 0.8% in MAK=/= versus 17.9 ± 0.6% in wild type, p < 0.05, n = 6) (Fig. 5B). These results suggest an increased ATP supply capacity (apparently mitochondrial) yet perturbed energetic communication between cellular locales of ATP production and consumption in MAK=/= muscles.



View larger version (14K):
[in this window]
[in a new window]
 
FIG. 5.
Disrupted intracellular communication between sites of ATP production and consumption in MAK=/= skeletal muscle. A, [18O]Pi/[18O]{gamma}-ATP ratio as an indicator of the Pi exchange rate between cellular ATP-producing and ATP-hydrolyzing sites. [18O]Pi and [18O]{gamma}-ATP measured in wild-type (n = 6) and MAK=/= (n = 6) GPS muscles paced for 3 min at 2 Hz. B, increased {gamma}-ATP phosphate turnover in MAK=/= skeletal muscle. Percentage of {gamma}-ATP phosphoryl oxygens replaced with 18O as an indicator of the cellular ATP synthesis capacity in wild-type (n = 6) and MAK=/= (n = 6) GPS muscles. WT, wild type.

 

Phosphotransfer Dynamics in MAK=/= Muscle—Metabolic demand and/or stress may cause redistribution of fluxes through phosphotransfer pathways (6, 16, 18, 19, 42, 54, 55). Therefore, we measured the relative contribution of AK- and CK- and alternative phosphotransfer reactions to total cellular phosphotransfer under resting and working conditions. Absence of both AK1 and M-CK did not affect total ATP turnover in wild-type or MAK=/= resting muscle, which were 11.4 ± 0.2 versus 11.5 ± 0.5 nmol ATP·min1·mg protein1, respectively (p > 0.05, n = 6) (Fig. 6A). However, in the active contracting state, total cellular ATP turnover increased by 114% in wild-type but only by 70% in MAK=/= muscle, suggesting a lower energetic capacity of AK1 and M-CK deficient myocytes. Indeed, in contracting MAK=/= muscle, total ATP turnover was lowered by 20% compared with wild type, i.e. 19.5 ± 1.4 and 24.3 ± 0.7 nmol ATP·min1·mg protein1 (n = 6, p < 0.05) (Fig. 6C), respectively. In wild-type muscle, the estimated AK flux increased from 1.9 ± 0.1 nmol·min1·mg protein1 in resting muscle to 5.6 ± 0.4 nmol·min1·mg protein1 in contracting muscle (n = 6, p < 0.05), an increase of 194%, which could account for 17 and 23% of total cellular ATP turnover, respectively (Fig. 6, B and D). Although the estimated CK flux was increased by 42% from 9.4 ± 0.3 (n = 6) to 13.3 ± 0.9 (n = 6) nmol·min1·mg protein1 in resting and contracting wild-type muscle, respectively (p < 0.05) (Fig. 6), the contribution of CK-mediated phosphotransfer to total cellular ATP turnover decreased from 83 to 55% in response to muscle workload. In the MAK=/= knock-out muscle, the residual AK flux was 0.48 ± 0.05 in the resting state and 0.80 ± 0.08 nmol·min1·mg protein1 in the contracting state. Under both conditions, AK-catalyzed phosphotransfer activity could account for 4% of total ATP turnover, indicating that a very limited AK capacity remained in MAK=/= muscles (Fig. 6, A and C). Indeed, residual AK activity in double mutant muscles was 44 ± 9 nmol ATP·min1·mg protein1 (n = 5), which is ~1–2% of total AK activity in the wild type. In mutant muscle, CK flux increased from 5.1 ± 0.2 at rest to 6.0 ± 0.4 nmol·min1·mg protein1 upon activation of contractions and accounted for 45 and 31% cellular ATP turnover, respectively (Fig. 6). Thus, the ablation of AK1 translated into a 75% decline in the contribution of AK catalysis to cellular ATP processing, a contribution further reduced (by 82%) under increased workload. The absence of M-CK translated into a 46 and 44% reduction in the contribution of CK catalysis to cellular ATP processing in resting and contracting muscles, respectively. Therefore, in the active state, the combined AK and CK contribution to cellular high energy phosphoryl transfer was reduced from 78% in the wild-type to 35% in MAK=/= muscle. This phosphotransfer deficit was partially compensated by glycolytic, hexokinase-catalyzed, and guanine nucleotide-dependent phosphoryl exchange mechanisms (Fig. 4). Contribution of such mechanisms increased from 9% in wild type to 39% in MAK=/=, leaving approximately 25–30% total metabolically active ATP unexplained. This could be accounted for by the remaining phosphotransfer systems, such as the glyceraldehyde-phosphate dehydrogenase/phosphoglycerate kinase enzyme couple (19, 33, 39, 56) and pyruvate kinase (39) or by diffusional type of ATP replenishment due to cytoarchitectural rearrangements (57).



View larger version (23K):
[in this window]
[in a new window]
 
FIG. 6.
Differential dynamics of phosphotransfer pathways in wild-type and MAK=/= muscles. A, maintained total ATP turnover in resting MAK=/= GPS muscle. Total ATP turnover obtained from 18O incorporation into cellular high energy phosphoryls measured in wild-type (n = 6) and MAK=/= (n = 6) GPS muscles at rest. B, contribution of AK- and CK-catalyzed phosphotransfer to total cellular ATP turnover in resting wild-type and MAK=/= GPS muscles. AK- and CK-catalyzed phosphotransfer expressed as the percentage of total ATP turnover in wild-type (n = 6) and MAK=/= (n = 6) GPS muscles at rest. C, reduced total ATP turnover in contracting MAK=/= GPS muscle. Total ATP turnover obtained from 18O incorporation into cellular high energy phosphoryls measured in wild-type (n = 6) and MAK=/= (n = 6) GPS muscles paced for 3 min at 2 Hz. D, contribution of AK- and CK-catalyzed phosphotransfer to total cellular ATP turnover in the working wild-type and MAK=/= GPS muscles. AK- and CK-catalyzed phosphotransfer expressed as the percentage of total ATP turnover in wild-type (n = 6) and MAK=/= (n = 6) GPS muscle paced for 3 min at 2 Hz. WT, wild type.

 


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
AK- and CK-catalyzed phosphotransfer reactions have been considered as essential mediators in cellular energetic and metabolic signaling processes (35, 18, 22). Skeletal muscles carrying a null mutation in either AK1 or M-CK genes demonstrate energetic abnormalities coupled with developmental adaptations and metabolic rearrangements within the cellular phosphotransfer pathways (6, 18, 24). The absence of AK1 causes an increased flux through the CK-catalyzed phosphotransfer (6), whereas absence of M-CK leads to increased AK-catalyzed phosphotransfer activity (18, 36). Here, metabolic consequences of combined disruption of the M-CK and AK1 genes in skeletal muscle as well as adaptive rearrangements were defined using 18O-metabolic labeling to monitor intracellular phosphotransfer dynamics.

Skeletal muscle devoid of M-CK and AK1 showed a severe decline in total muscle AK and CK activities, which translated into a 54 and 85% reduction in CrP and ATP {beta}-phosphoryl turnover, respectively. The remaining CK activity can be attributed to the ScCKmit isoform still present in mitochondria of MAK=/=. The reduction in {beta}-phosphoryl turnover is apparently less severe in MAK=/= compared with the single AK1 knock-out muscle where a 99% reduction in {beta}-phosphoryl turnover was observed (6), suggesting that MAK=/= muscles are more proficient in recruiting a functional reserve of the {beta}-phosphoryl transfer capacity. Increased flux capacity through the AK3-catalyzed GTP:AMP phosphotransfer reaction could underlie this phenomenon as the high energy phosphate from GTP is transferred to AMP followed by conversion to ATP by oxidative phosphorylation in the mitochondrial matrix (9), in line with the increased {gamma}-GTP turnover in MAK=/= muscles.

The presence of cytosolic CK and AK within local microenvironments of actomyosin ATPases facilitates transfer of high energy phosphoryls to regenerate ATP, thus supporting the kinetic and thermodynamic efficiency of muscle contraction (5, 47). Indeed, resting and contracting MAK=/= knock-out muscles displayed overall lower ATP/ADP and higher ADP/AMP ratios compared with wild type. This suggests that AK1 and/or M-CK is not only necessary for local ATP regeneration but also for equilibrating adenine nucleotide gradients throughout the entire cytosolic pool. Inefficient local and global communication in MAK=/= muscle is manifested in a decreased overall cellular ATP turnover and lower Pi levels in response to increased workload. This may result from insufficient delivery of ATP to cellular ATPase sites despite an increased ATP synthesis capacity as indicated from increased 18O labeling of {gamma}-ATP.

The interaction between AK-CK and glycolytic phosphotransfer systems is critical for energy supply and local ATP regeneration in different cell types (4, 6, 16, 33, 39, 48, 53). In muscles deficient in both AK1 and M-CK, glycolysis is probably the only remaining major cytosolic phosphotransfer circuit. Glycolytic metabolism could safeguard maintenance of appropriate ATP/ADP ratios in the myosin ATPase microenvironment required for efficient contractile cycles (58, 59). Indeed, the overall concentration and turnover rate of the first glycolytic intermediate, Glc-6-P, was more than doubled in MAK=/= mice. Contribution of glycolytic hexokinase-catalyzed phosphotransfer increased from 8% in wild-type to 37% in MAK=/= muscles, whereas combined activities of guanylate phosphotransfer enzymes such as succinate thiokinase, NDPK, and guanylate kinase could account for only 0.6 and 1.8% of total cellular ATP turnover in wild-type and MAK=/= muscles, respectively. Therefore, enhanced ATP production and distribution by glycolytic enzymes may have a general compensatory role in sustaining physiological relevant ATPase activity in MAK=/= muscle.

Localization of glycolytic enzymes within myofibrils at the I- and M-bands as well as their binding to mitochondrial outer membrane provides a network capacity for transferring and distributing high energy phosphoryls (13, 60, 61). This global glycolytic function integrating mitochondrial ATP production with cytosolic sites of ATP consumption may underlie increased coupling between high energy phosphoryl flux through glycolytic metabolism and muscle contraction in MAK=/= mice. Indeed, the apparently increased glycolytic flux in MAK=/= skeletal muscle was paralleled by the increased ATP synthesis rate and enhanced metabolic labeling of {gamma}-GTP. This result can be explained by elevated Krebs cycle activity (42) coupled to increased oxidative phosphorylation activity. The finding of a significant increase in the volume of intermyofibrillar mitochondria in MAK=/= muscles2 similar to that seen in AK1 and M-CK single mutants (6, 24) and in other muscles with compromised energy metabolism (6264) supports this conclusion. Thus, it is conceivable that MAK=/= muscles combine the advantages of increased glycolytic flux and improved mitochondrial potential for aerobic ATP production to compensate for the loss of M-CK and AK1 supported high energy phosphoryl transfer activities.

Measurements in isolated actomyosin showed that the onset of contraction was ~12–20-fold faster if ATP was provided via AK1 or M-CK rather than by direct ATP supply through diffusional nucleotide exchange. In this regard, previous functional studies on fast-twitch muscles of mice lacking M-CK have demonstrated lack of burst activity (24) and compromised ability to sustain contraction force (43), in line with loss of preferential access to ATP via the CK reaction. Similarly, AK1 activity facilitates muscle relaxation, indicating that removal of contraction-produced ADP by AK1 and its phosphorylation to ATP takes place much faster than diffusional exchange of ADP to ATP (47). As ultra-fast local and global ATP regeneration is required to sustain contractile activity in fast-twitch muscle (24, 52), this would underscore the particular importance of CK- and AK-catalyzed phosphotransfer in these muscle types. Moreover, mice carrying a single mutation in the AK1 or M-CK gene show more pronounced adaptations at the molecular and architectural level in their fastrather than slow-twitch fibers (24, 3739). Thus, tight coordination between cellular sites of ATP consumption and ATP generation by the complete set of high energy phosphoryl transfer pathways would not only be essential for safeguarding cellular energetic economy (6, 33, 54, 65) but also for preserving the differential physiological contractile characteristics of slow- and fast-twitch muscles. Studies in vivo with measurement of physiological performance of intact muscle will be eventually necessary to reveal further details.

In summary, this study demonstrates that lack of the M-CK and AK1 catalytic capacity abolished CK- and AK-mediated efficient high energy phosphoryl delivery to skeletal muscle actomyosin ATPase accompanied with compromised ability to sustain ATP turnover and to maintain nucleotide ratios in response to functional load. An apparent compensatory redistribution of high energy phosphoryl flux through glycolytic and guanylate phosphotransfer pathways lessened the genetic stress-induced energetic burden. The results provide reverse genetics-based evidence for the physiological significance of an integrated cellular phosphotransfer and energy-homeostasis network composed of complementary enzymatic pathways.


    FOOTNOTES
 
* This work was supported by Nederlandse Organisatie voor Wetenschappelijk Onderzoek-Zorgonderzoek Nederland Medische Wetenschappen (NWO-ZONMW) Grant 901-01-095, the Nederlandse Kanker-bestrijding (KWF) Grant KUN 98-1808, National Institutes of Health Grant HL64822, and the American Heart Association. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

To whom correspondence should be addressed: Dept. of Cell Biology, Nijmegen Center for Molecular Life Sciences University Medical Center, Medical Faculty University Nijmegen, P. O. Box 9101, 6500 HB Nijmegen, The Netherlands. Tel.: 31-24-3614329/3614287; Fax: 31-24-3615317; E-mail: b.wieringa{at}ncmls.kun.nl.

1 The abbreviations used are: CK, creatine kinase; AK, adenylate kinase; ScCKmit, skeletal muscle containing an additional mitochondrial CK isoform; NDPK, nucleoside diphosphokinase; GPS, gastrocnemius-plantaris-soleus; CrP, creatine phosphate; Glc-6-P, glucose 6-phosphate; PEP, phosphoenolpyruvate; MM-CK, muscle-type dimeric cytosolic CK. Back

2 E. Janssen, unpublished observation. Back



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Wallimann, T., Wyss, M., Brdiczka, D., Nicolay, K., and Eppenberger, H. M. (1992) Biochem. J. 281, 21–40[Medline] [Order article via Infotrieve]
  2. Saks, V., Dos Santos, P., Gellerich, F. N., and Diolez, P. (1998) Mol. Cell. Biochem. 184, 291–307[CrossRef][Medline] [Order article via Infotrieve]
  3. Savabi, F. (1994) Mol. Cell. Biochem. 133–134, 145–152
  4. Dzeja, P. P., and Terzic, A. (1998) FASEB J. 12, 523–529[Abstract/Free Full Text]
  5. Bessman, S. P., and Carpenter, C. L. (1985) Annu. Rev. Biochem. 54, 831–862[CrossRef][Medline] [Order article via Infotrieve]
  6. Janssen, E., Dzeja, P. P., Oerlemans, F., Simonetti, A. W., Heerschap, A., de Haan, A., Rush, P. S., Terjung, R. R., Wieringa, B., and Terzic, A. (2000) EMBO J. 19, 6371–6381[CrossRef][Medline] [Order article via Infotrieve]
  7. Noda, L. H. (1973) in The Enzymes (Boyer, P. D., ed), Academic Press, Orlando, FL
  8. Atkinson, D. E. (1977) Cellular Energy Metabolism and Its Regulation, Academic Press, Orlando, FL
  9. Tanabe, T., Yamada, M., Noma, T., Kajii, T., and Nakazawa, A. (1993) J. Biochem. (Tokyo) 113, 200–207[Abstract/Free Full Text]
  10. Van Rompay, A. R., Johansson, M., and Karlsson, A. (1999) Eur. J. Biochem. 261, 509–517[Medline] [Order article via Infotrieve]
  11. Yoneda, T., Sato, M., Maeda, M., and Takagi, H. (1998) Brain Res. Mol. Brain Res. 62, 187–195[Medline] [Order article via Infotrieve]
  12. Collavin, L., Lazarevic, D., Utrera, R., Marzinotto, S., Monte, M., and Schneider, C. (1999) Oncogene. 18, 5879–5888[CrossRef][Medline] [Order article via Infotrieve]
  13. Wegmann, G., Zanolla, E., Eppenberger, H. M., and Wallimann, T. (1992) J. Muscle Res. Cell Motil. 13, 420–435[CrossRef][Medline] [Order article via Infotrieve]
  14. Elvir Mairena, J. R., Jovanovic, A., Gomez, L. A., Alekseev, A. E., and Terzic, A. (1996) J. Biol. Chem. 271, 31903–31908[Abstract/Free Full Text]
  15. Janssen, E., Kuiper, J., Hodgson, D., Zingman, L. V., Alekseev, A. E., Terzic, A., and Wieringa, B. (2003) Mol. Cell. Biochem., in press
  16. Zeleznikar, R. J., Dzeja, P. P., and Goldberg, N. D. (1995) J. Biol. Chem. 270, 7311–7319[Abstract/Free Full Text]
  17. Dzeja, P. P., Zeleznikar, R. J., and Goldberg, N. D. (1996) J. Biol. Chem. 271, 12847–12851[Abstract/Free Full Text]
  18. Dzeja, P. P., Zeleznikar, R. J., and Goldberg, N. D. (1998) Mol. Cell. Biochem. 184, 169–182[CrossRef][Medline] [Order article via Infotrieve]
  19. Pucar, D., Janssen, E., Dzeja, P. P., Juranic, N., Macura, S., Wieringa, B., and Terzic, A. (2000) J. Biol. Chem. 275, 41424–41429[Abstract/Free Full Text]
  20. Pucar, D., Bast, P., Gumina, R. J., Lim, L., Drahl, C., Juranic, N., Macura, S., Janssen, E., Wieringa, B., Terzic, A., and Dzeja, P. P. (2002) Am. J. Physiol. 283, H776–H782
  21. Dzeja, P. P., Vitkevicius, K. T., Redfield, M. M., Burnett, J. C., and Terzic, A. (1999) Circ. Res. 84, 1137–1143[Abstract/Free Full Text]
  22. Carrasco, A. J., Dzeja, P. P., Alekseev, A. E., Pucar, D., Zingman, L. V., Abraham, M. R., Hodgson, D., Bienengraeber, M., Puceat, M., Janssen, E., Wieringa, B., and Terzic, A. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 7623–7628[Abstract/Free Full Text]
  23. Dzeja, P. P., Bortolon, R., Perez-Terzic, C., Holmuhamedov, E. L., and Terzic, A. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 10156–10161[Abstract/Free Full Text]
  24. van Deursen, J., Heerschap, A., Oerlemans, F., Ruitenbeek, W., Jap, P., ter Laak, H., and Wieringa, B. (1993) Cell 74, 621–631[CrossRef][Medline] [Order article via Infotrieve]
  25. Rossi, A. M., Eppenberger, H. M., Volpe, P., Cotrufo, R., and Wallimann, T. (1990) J. Biol. Chem. 265, 5258–5266[Abstract/Free Full Text]
  26. Wyss, M., Smeitink, J., Wevers, R. A., and Wallimann, T. (1992) Biochim. Biophys. Acta. 1102, 119–166[CrossRef][Medline] [Order article via Infotrieve]
  27. Veksler, V. I., Kuznetsov, A. V., Anflous, K., Mateo, P., van Deursen, J., Wieringa, B., and Ventura Clapier, R. (1995) J. Biol. Chem. 270, 19921–19929[Abstract/Free Full Text]
  28. Schlattner, U., and Wallimann, T. (2000) J. Biol. Chem. 275, 17314–17320[Abstract/Free Full Text]
  29. Beutner, G., Ruck, A., Riede, B., Welte, W., and Brdiczka, D. (1996) FEBS Lett. 396, 189–195[CrossRef][Medline] [Order article via Infotrieve]
  30. Brdiczka, D. (1994) Biochim. Biophys. Acta. 1187, 264–269[Medline] [Order article via Infotrieve]
  31. Askenasy, N., and Koretsky, A. P. (2002) Am. J. Physiol. 282, C338–C346
  32. Ottaway, J. H., and Mowbray, J. (1977) Curr. Top. Cell Regul. 12, 107–208[Medline] [Order article via Infotrieve]
  33. Dzeja, P. P., Redfield, M. M., Burnett, J. C., and Terzic, A. (2000) Curr. Cardiol. Rep. 2, 212–217[Medline] [Order article via Infotrieve]
  34. Abraham, M. R., Selivanov, V. A., Hodgson, D. M., Pucar, D., Zingman, L. V., Wieringa, B., Dzeja, P. P., Alekseev, A. E., and Terzic, A. (2002) J. Biol. Chem. 277, 24427–24434[Abstract/Free Full Text]
  35. O'Gorman, E., Beutner, G., Wallimann, T., and Brdiczka, D. (1996) Biochim. Biophys. Acta. 1276, 161–170[Medline] [Order article via Infotrieve]
  36. LaBella, J. J., Daood, M. J., Koretsky, A. P., Roman, B. B., Sieck, G. C., Wieringa, B., and Watchko, J. F. (1998) J. Appl. Physiol. 84, 1166–1173[Abstract/Free Full Text]
  37. de Groof, A. J., Oerlemans, F. T., Jost, C. R., and Wieringa, B. (2001) Muscle Nerve 24, 1188–1196[CrossRef][Medline] [Order article via Infotrieve]
  38. de Groof, A. J., Smeets, B., Groot Koerkamp, M. J., Mul, A. N., Janssen, E. E., Tabak, H. F., and Wieringa, B. (2001) FEBS Lett. 506, 73–78[CrossRef][Medline] [Order article via Infotrieve]
  39. Janssen, E., De Groof, A., Wijers, M., Fransen, J., Dzeja, P. P., Terzic, A., and Wieringa, B. (2003) J. Biol. Chem. 278, 12937–12945[Abstract/Free Full Text]
  40. Steeghs, K., Oerlemans, F., de Haan, A., Heerschap, A., Verdoodt, L., de Bie, M., Ruitenbeek, W., Benders, A., Jost, C., van Deursen, J., Tullson, P., Terjung, R., Jap, P., Jacob, W., Pette, D., and Wieringa, B. (1998) Mol. Cell. Biochem. 184, 183–194[CrossRef][Medline] [Order article via Infotrieve]
  41. Zeleznikar, R. J., and Goldberg, N. D. (1991) J. Biol. Chem. 266, 15110–15119[Abstract/Free Full Text]
  42. Zeleznikar, R. J., Heyman, R. A., Graeff, R. M., Walseth, T. F., Dawis, S. M., Butz, E. A., and Goldberg, N. D. (1990) J. Biol. Chem. 265, 300–311[Abstract/Free Full Text]
  43. Steeghs, K., Benders, A., Oerlemans, F., de Haan, A., Heerschap, A., Ruitenbeek, W., Jost, C., van Deursen, J., Perryman, B., Pette, D., Bruckwilder, M., Koudijs, J., Jap, P., Veerkamp, J., and Wieringa, B. (1997) Cell 89, 93–103[CrossRef][Medline] [Order article via Infotrieve]
  44. Wallimann, T., Moser, H., and Eppenberger, H. M. (1983) J. Muscle Res. Cell Motil. 4, 429–441[CrossRef][Medline] [Order article via Infotrieve]
  45. Honig, C. R. (1968) Am. J. Physiol. 214, 357–364[Free Full Text]
  46. Reddy, Y. S., Wyborny, L., Lewis, R. M., and Schwartz, A. (1976) Cardiovasc. Res. 10, 129–135[Medline] [Order article via Infotrieve]
  47. Savabi, F., Geiger, P. J., and Bessman, S. P. (1986) Biochem. Med. Metab. Biol. 35, 227–238[CrossRef][Medline] [Order article via Infotrieve]
  48. Kraft, T., Hornemann, T., Stolz, M., Nier, V., and Wallimann, T. (2000) J. Muscle Res. Cell Motil. 21, 691–703[CrossRef][Medline] [Order article via Infotrieve]
  49. Ray, N. B., and Mathews, C. K. (1992) Curr. Top. Cell Regul. 33, 343–357[Medline] [Order article via Infotrieve]
  50. Lu, Q., and Inouye, M. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 5720–5725[Abstract/Free Full Text]
  51. Stolworthy, T. S., and Black, M. E. (2001) Protein Eng. 14, 903–909[Abstract/Free Full Text]
  52. Schiaffino, S., and Reggiani, C. (1996) Physiol. Rev. 76, 371–423[Abstract/Free Full Text]
  53. Korge, P. (1995) Sports Med. 20, 215–225[Medline] [Order article via Infotrieve]
  54. Pucar, D., Dzeja, P. P., Bast, P., Juranic, N., Macura, S., and Terzic, A. (2001) J. Biol. Chem. 276, 44812–44819[Abstract/Free Full Text]
  55. in't Zandt, H. J., Oerlemans, F., Wieringa, B., and Heerschap, A. (1999) NMR Biomed. 12, 327–334[CrossRef][Medline] [Order article via Infotrieve]
  56. Sako, E. Y., Kingsley-Hickman, P. B., From, A. H., Foker, J. E., and Ugurbil, K. (1988) J. Biol. Chem. 263, 10600–10607